As of August 28, 2026, XORTX Therapeutics Inc. (XRTX) has a DilutionWatch DilutionScore of 71/100, rated HIGH dilution risk. XORTX Therapeutics Inc. has a market capitalization of $3.98M, 12.99M shares outstanding, 1 institutional holders tracked.
This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.
Dilution Forecast
☀️
Clear
No significant dilution signals
model est. 5%
📉 Score Deterioration
model 10%
• Score in HIGH risk zone (71/100)
Market Data
Market Cap$3.98M
Shares Outstanding12.99M
Float1.37M
Cash$250.3K
Debt$15.1K
Short InterestN/A
Institutional Holdings
QoQ: ↓ 100.0% shares (2026Q1 vs prior)
1 institutional holders · 47 shares
#1
TD Waterhouse Canada Inc.
47 shares
Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.
Short Interest
Short Interest20.6K
Days to Cover1.3
% of Float1.5%
FINRA data as of Jul 31, 2026
Recent SEC Activity
Full SEC filing analysis available with free account
→
Recent News
No recent news
Factual XRTX Dilution Snapshot
XORTX Therapeutics Inc. (XRTX) has a DilutionScore of 71/100, rated High dilution risk. Score date: August 28, 2026.
- Recent SEC activity tracked for XRTX: EFFECT on 2026-02-17.
This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.
Track XRTX Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking XRTX — Free
Real-time SEC alerts
DilutionScore™ tracking
No credit card required
More Research for XRTX
Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.